Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia

Neuroscience

Volumn 94, Issue 1, 1999, Pages 21-31

  Holt, D J ^a,b   Herman, M M ^c   Hyde, T M ^c   Kleinman, J E ^c   Sinton, C M ^d   German, D C ^d   Hersh, L B ^e   Graybiel, A M ^f   Saper, C B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Basal ganglia; Cholinergic; Human; Interneuron; Schizophrenia; Striatum

Indexed keywords

ARTICLE; BASAL GANGLION; CELL ULTRASTRUCTURE; CHOLINERGIC TRANSMISSION; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INTERNEURON; METABOLIC REGULATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR DENSITY; SCHIZOPHRENIA;

ADULT; AGED; AGED, 80 AND OVER; BRAIN CHEMISTRY; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL COUNT; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; CORPUS STRIATUM; HUMANS; INTERNEURONS; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0032851146     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00279-1     Document Type: Article

References (93)

1. Akil M., Brewer G.J. Psychiatric and behavioral abnormalities in Wilson's disease. Adv. Neurol. 65:1995;171-178.
2. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. A. Rev. Neurosci. 9:1986;357-381.
3. Aosaki T., Kimura M., Graybiel A.M. Temporal and spatial characteristics of tonically active neurons of the primate's striatum. J. Neurophysiol. 73:1995;1234-1252.
4. 3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci. Lett. 232:1997;13-16.
5. Beckmann H., Lauer M. The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiat. Res. 68:1997;99-109.
6. Bird E.D., Barnes J., Iversen L.L., Spokes E.G., Mackay A.V.P., Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyltransferase activity in schizophrenia and related psychoses. Lancet. iii:1977;1157-1159.
7. Bird E.D., Spokes E.G., Iversen L.L. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain. 102:1979;347-360.
8. Biver F., Goldman S., Luxen A., Delvenne V., De Maertelaer V., De La Fuente J., Mendlewicz J., Lotstra F. Altered frontostriatal relationship in unmedicated schizophrenic patients. Psychiat. Res. 61:1995;161-171.
9. Braak H., Braak E. Neuronal types in the striatum of man. Cell Tiss. Res. 277:1982;319-342.
10. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Archs gen. Psychiat. 49:1992;921-926.
11. Brene S., Lindefors N., Herrera-Marschitz M., Persson H. Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen. Expl Brain Res. 83:1990;96-104.
12. Bruce G., Wainer B.H., Hersh L.B. Immunoaffinity purification of human choline acetyltransferase: comparison of the brain and placental enzymes. J. Neurochem. 45:1985;611-620.
13. Buchanan R.W. Jr, Breier A., Kirkpatrick B., Elkashef A., Munson R.C., Gellad F., Carpenter W.T. Structural abnormalities in deficit and nondeficit schizophrenia. Am. J. Psychiat. 150:1993;59-65.
14. Buchsbaum M.S. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schiz. Bull. 16:1990;377-387.
15. Buchsbaum M.S., Haier R.J., Potkin S.G., Nuechterlein K., Bracha H.S., Katz M., Lohr J., Wu J., Lottenberg S., Jerabek P.A. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Archs gen. Psychiat. 49:1992;935-942.
16. Bull G., Hebb C., Ratkovic D. Choline acetyltransferase activity of human brain tissue during development and at maturity. J. Neurochem. 17:1970;1505-1516.
17. Cedarbaum J. M. and Schleifer L. S. (1990) Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In The Pharmacological Basis of Therapeutics (eds Gilman A. G., Rall T. W., Nies A. S. and Taylor P.), 8th edn, pp. 463-484. Pergamon, New York.
18. Celio M.R. Calbindin D-28-k and parvalbumin in the rat nervous system. Neuroscience. 35:1990;375-475.
19. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiat. 151:1994;1430-1436.
20. Chakos M.H., Lieberman J.A., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics and clozapine. Lancet. 343:1995;456-457.
21. Cicchetti F., Beach T.G., Parent A. Chemical phenotype of calretinin interneurons in the human brain. Synapse. 30:1998;284-297.
22. Cicchetti F., Gould P.Y., Parent A. Neurons containing calretinin and expressing substance P (NK1) receptors in the striatum of normal and Huntington's disease patients. Soc. Neurosci. Abstr. 21:1995;1187.
23. Cohen B.M., Wan W. The thalamus as a site of action of antipsychotic drugs. Am. J. Psychiat. 153:1995;104-106.
24. Consolo S., Samanin R., Bianchi S., Ghezzi D. Supersensitivity of the cholinergic response to apomorphine in the striatum following denervation or disuse supersensitivity of dopaminergic receptors in the rat. Brain Res. 155:1978;45-54.
25. Cross A.J., Owen F. The activities of glutamic acid decarboxylase and choline acetyltransferase in post-mortem brains of schizophrenics and controls. Biochem. Soc. Trans. 7:1979;145-146.
26. Cummings J.L. Frontal-subcortical circuits and human behavior. Archs Neurol. 50:1993;873-879.
27. Cummings J.L. Behavioral and psychiatric symptoms associated with Huntington's disease. Adv. Neurol. 65:1995;179-186.
28. Dean B., Crook J.M., Oeskin K., Hill C., Keks N., Copolov D.L. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Molec. Psychiat. 1:1996;54-58.
29. Deutch A.Y., Ongur D., Duman R.S. Antipsychotic drugs induce fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience. 66:1995;337-346.
30. Diecken R.F., Calabrese G., Merrin E.L., Fein G., Weiner M.W. Basal ganglia phosphorous metabolism in chronic schizophrenia. Am. J. Psychiat. 152:1995;126-129.
31. DiFiglia M. Synaptic organization of cholinergic neurons in the monkey striatum. J. comp. Neurol. 255:1987;245-258.
32. Domino E.F., Krause R.R., Bowers J. Various enzymes involved with putative neurotransmitters. Regional distribution in the brain of deceased mentally normal, chronic schizophrenics or organic brain syndrome patients. Archs gen. Psychiat. 29:1973;195-201.
33. Eckenstein F., Sofroniew M.V. Identification of central cholinergic neurons containing both acetyltransferase and of central neurons containing only acetylcholinesterase. J. Neurosci. 3:1983;2286-2291.
34. Elkashef A.M., Buchanan R.W., Gellad F., Munson R.C., Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am. J. Psychiat. 151:1994;752-755.
35. Fortin M., Parent A. Patches in the striatum of squirrel monkeys are enriched with calretinin fibers but devoid of calretinin cell bodies. Neurosci. Lett. 182:1994;51-54.
36. Gearing M., Wilson R.W., Unger E.R., Shelton E.R., Chan H.W., Masters C.L., Bayreuther K., Mirra S.S. Amyloid precursor protein (APP) in the striatum in Alzheimer's disease - an immunohistochemical study. J. Neuropath. exp. Neurol. 52:1993;22-30.
37. Geula C., Tokuno H., Hersh L., Mesulam M.-M. Human striatal cholinergic neurons in development, aging and Alzheimer's disease. Brain Res. 508:1990;310-312.
38. Goldman P.S., Rosvold H.E. Localization of function within the dorsolateral prefrontal cortex of the rhesus monkey. Expl Neurol. 27:1970;291-304.
39. Goldman P.S., Rosvold H.E. The effects of selective caudate lesions in infant and juvenile Rhesus monkeys. Brain Res. 43:1972;53-66.
40. Granacher R.P., Baldessarini R.J. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Archs gen. Psychiat. 32:1975;375-380.
41. Graybiel A.M., Aosaki T., Flaherty A.W., Kimura M. The basal ganglia and adaptive motor control. Science. 265:1995;1826-1831.
42. Graybiel A.M. The basal ganglia and cognitive pattern generators. Schiz. Bull. 23:1997;459-469.
43. Guillery R.W., Herrup K. Quantification without pontification: choosing a method for counting objects in sectioned tissues. J. comp. Neurol. 386:1997;2-7.
44. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. Archs gen. Psychiat. 54:1997;225-232.
45. Haber S.N., Fudge J.L. The interface between dopamine neurons and the amygdala: implications for schizophrenia. Schiz. Bull. 23:1997;471-482.
46. Harrington K.A., Augood S.J., Faull R.L.M., McKenna P.J., Emson P.C. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study. Molec. Brain Res. 33:1995;333-342.
47. Heckers S., Heinsen H., Heinsen Y., Beckmann H. Cortex, white matter, and basal ganglia in schizophrenia - a volumetric postmortem study. Biol. Psychiat. 29:1991;556-566.
48. Heckers S., Mash D., Guela C., Mesulam M.-M. Basal forebrain and striatal cholinergic neurons in schizophrenia. Soc. Neurosci. Abstr. 19:1993;838.
49. Hokama H., Shenton M.E., Nestor P.G., Kikinis R., Levitt J.J., Metcalf D., Wible C.G., O'Donnell B.F., Jolesz F.A., McCarley R.W. Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study. Psychiat. Res: Neuroimaging. 61:1995;209-229.
50. Holcomb H.H., Cascella N.G., Thaker G.K., Medoff D.R., Dannals R.F., Tamminga C.A. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiat. 153:1996;41-49.
51. Holt D.J., Graybiel A.M., Hyde T.M. Decreased density of cholinergic interneurons in the striatum of schizophrenics. Soc. Neurosci. Abstr. 20:1994;784.
52. Holt D.J., Hersh L.B., Saper C.B. Cholinergic innervation of the human striatum: a three compartment model. Neuroscience. 74:1996;67-87.
53. Holt D. J. (1996) Chemoarchitecture of the Human Striatum. PhD dissertation, The University of Chicago, 216 pp.
54. Holt D.J., Graybiel A.M., Saper C.B. Neurochemical architecture of the human striatum. J. comp. Neurol. 384:1997;1-25.
55. Hoover J.E., Strick P.L. Multiple output channels in the basal ganglia. Science. 259:1993;819-821.
56. Jernigan T.L., Zisook S., Heaton R.K., Moranville J.T., Hesselink J.R., Braff D.L. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Archs gen. Psychiat. 48:1991;881-890.
57. Keshevan M., Bagwell W., Haas G., Sweeney J., Schooler N., Pettegrew J. Changes in caudate volume with neuroleptic treatment. Lancet. 344:1994;1434.
58. Kimura H., McGeer P.L., Peng J.H., McGeer E.G. The central cholinergic system studied by choline acetyltransferase immunohistochemistry in the cat. J. comp. Neurol. 200:1981;151-201.
59. Kitt C.A., Levey A.I., Freidmant D.P. Immunocytochemical visualization of cholinergic fibers in monkey neocortex: enhanced visualization using silver nitrate. Soc. Neurosci. Abstr. 14:1988;630-631.
60. Klawans H.L., Westheimer R., Goetz C.C. A pharmacological model of the pathophysiology of schizophrenia. Dis. nerv. Syst. 36:1975;267-275.
61. Kraepelin E. (1919) Dementia Praecox and Paraphrenia. Livingstone, Edinburgh.
62. Kulik A.V., Wilbur R. Delirium and stereotypy from anticholinergic antiparkinson drugs. Prog. Neuropsychopharmac. biol. Psychiat. 6:1982;75-82.
63. Lapper S.R., Bolam J.P. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience. 51:1992;533-545.
64. Lehericy S., Hirsh E.C., Cervera P. Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer's disease. Proc. natn. Acad. Sci. U.S.A. 86:1989;8580-8584.
65. Login I.S. D2 dopamine receptor activation inhibits basal and forskolin-evoked acetylcholine release from dissociated striatal cholinergic interneurons. Brain Res. 749:1997;147-151.
66. Mahadik S.P., Laev H., Korenovsky A., Karpiak S.E. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol. Psychiat. 24:1988;199-217.
67. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia. Fedn Proc. 32:1973;200-205.
68. McGeer P.L., McGeer E.G. Possible changes in striatal and limbic cholinergic systems in schizophrenia. Archs gen. Psychiat. 34:1977;1319-1323.
69. Meredith G.E., Wouterlood F.G. Hippocampal and midline thalamic fibers and terminals in relation to the choline acetyltransferase-immunoreactive neurons in nucleus accumbens of the rat: a light and electron microscopic study. J. comp. Neurol. 296:1990;204-221.
70. Miller D.D., Andreasen N.C., O'Leary D.S., Rezai K., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology. 17:1997;230-240.
71. Murray A.M., Hyde T.M., Knable M.B., Herman M.M., Bigelow L.B., Carter J.M., Weinberger D.R., Kleinman J.E. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15:1995;2186-2191.
72. Murugaiah K., Mann S., Theodorou A.E., Jenner P., Marsden C.D. Increased striatal acetylcholine after 14 months cis-flupenthioxol treatment in rats suggests functional supersensitivity of dopamine receptors. Life Sci. 31:1982;181-188.
73. Nelson P.T., Marton L., Saper C.B. Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study. Brain Res. 600:1993;285-297.
74. Oder W., Grimm G., Kollegger H., Fereenci P., Schneider B., Deecke L. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J. Neurol. 238:1991;281-287.
75. Oyanagi K., Takahashi H., Wakabayashi K., Ikuta F. Selective involvement of large neurons in the neostriatum of Alzheimer's disease and senile dementia: a morphometric investigation. Brain Res. 411:1987;205-211.
76. Oyanagi K., Takahashi H., Wakabayashi K., Ikuta F. Selective decrease of large neurons in the neostriatum in progressive supranuclear palsy. Brain Res. 458:1988;218-223.
77. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Archs gen. Psychiat. 47:1990;1023-1028.
78. Parent A., Csonka C., Etienne P. The occurrence of large acetylcholinesterase-containing neurons in human neostriatum as disclosed in normal and Alzheimer-diseased brains. Brain Res. 291:1984;154-158.
79. Parent A., Cicchetti F., Beach T.G. Calretinin-immunoreactive neurons in the human striatum. Brain Res. 674:1995;347-351.
80. Parent A., Cicchetti F., Beach T.G. Immunocytochemical characteriziation of neurons expressing calretinin in human striatum. Brain Path. 6:1996;355.
81. Pedata F., Sorbi S., Pepeu G. Choline high-affinity uptake and metabolism and choline acetyltransferase activity in the striatum of rats chronically treated with neuroleptics. J. Neurochem. 35:1980;606-611.
82. Pollack A.E., Wooten G.F. D2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic interneurons. Molec. Brain Res. 13:1992;35-41.
83. Potkin S.G., Buchsbaum M.S., Jin Y., Tang C., Telford J., Friedman G., Lottenberg S., Najafi A., Gulasekaram B., Costa J. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J. clin. Psychiat. 55:(Suppl. B):1994;63-66.
84. Roberts R.C., Conley R., Kung L., Peretti F.J., Chute D.J. Reduced striatal spine size in schizophrenia: a postmortem ultrastructural study. NeuroReport. 7:1996;1214-1218.
85. Rupniak N.M.J., Briggs M.M., Peterson M.M. Differential alterations in striatal acetylcholine function in rats during 12 months' continuous adminstration of haloperidol, sulpiride, or clozapine. Clin. Neuropharmac. 9:1986;282-292.
86. Saper C.B., German D.C., White C.L. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology. 35:1985;1089-1095.
87. Saper C.B. Any way you cut it: a new journal policy for the use of unbiased counting methods. J. comp. Neurol. 5:1996;5.
88. Selden N., Guela C., Hersh L., Mesulam M.M. Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience. 60:1994;621-636.
89. Siegel B.V. Jr, Buchsbaum M.S., Bunney W.E., Gottschalk L.A., Haier R.J., Lohr J.B., Lottenberg S., Najafi A., Nuechterlein K.H., Potkin S.G. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenics. Am. J. Psychiat. 150:1993;1325-1336.
90. Spokes E.G.S. An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post-mortem brain tissue. Brain. 102:1979;333-346.
91. Suenaga T., Hirano A., Llena J.F., Yen S.-H., Dickson D.W. Modified Bielschowsky's stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta neuropath. Berlin. 80:1990;280-286.
92. Swaller B., Buchwald P., Blumcke I., Celio M.R., Hunziker W. Characterization of a polyclonal antiserum against the purified human recombinant calcium binding protein calretinin. Cell Calcium. 14:1993;639-648.
93. Yelnik J., Francois C., Percheron G., Tande D. Morphological taxonomy of the neurons of the primate striatum. J. comp. Neurol. 313:1991;273-294.